Please select the eligibility criteria that correspond to the clinical trial below.
Title: Application for Self-Monitoring of Cardiovascular Risk
Brief Summary: Patients who recently suffered a heart attack will use a smart-phone/computer application during cardiac rehabilitation to reduce their risk of a future attack, their re-hospitalizations, their cost of care, and increase their quality of life.


Options:
A: Inclusion Criteria:

* Recently underwent PCI.
* Are eligible for enrollment to the Cardiovascular Health Clinic (CVHC)
* Do not have any physical impediments to physical activity
* Do not have any impediments to physically attending the Mayo Clinic's CVHC
* They are willing to incorporate the software application into their CR
* They must have access to the internet

Exclusion Criteria:

* - They are unable or unwilling to enroll in CR
* They are unable to physically attend Mayo Clinic's CVHC CR Program
* They are unwilling to incorporate the Personal Health Assistant into their CR
B: Inclusion Criteria:

* Post-MI hospital discharge within 2 weeks
* Enrolled in cardiac rehabilitation
* Prescribed anti-platelets, beta-blockers, ACE-inhibitors or ARBs, and/or statins on 1x/day regimen (for medication adherence trial)
* Prescribed exercise regimen (for exercise trial)
* Ability to read and write English
* Possession of a cell phone with text messaging capability

Exclusion Criteria:

* Age \< 18
* Incarcerated individuals
* Unable to read and write English
* Not in possession of a cell phone
* Patients prescribed medication regimen \> 1x/day
C: Inclusion Criteria:

All of them:

* Age ≤ 80 years.
* Stable Ischemic heart disease, revascularized by angioplasty or underwent surgery by coronary bypass \<= one year from the acute episode.
* Good cognitive level.
* Ability to perform aerobic exercise tape or cycle ergometer.
* Understand the use of a mobile Smartphone or Tablet.
* Signature of informed consent.

And at least one of the following:

* Ventricular dysfunction by Ejection Fraction (FE) 40 - 50%.
* Functional capacity 5-7 metabolic equivalents (METS).
* Raising the blood pressure with the effort.

Exclusion Criteria:

* Presence of malignant arrhythmias such as ventricular fibrillation outside the acute phase of Acute myocardial infarction (AMI) (\> 24 h after AMI), ventricular tachycardia, Atrioventricular block of 2nd degree and 3rd degree, Atrial fibrilation (FA) in patients with Wolf Parkinson White, fibrillation or paroxysmal atrial flutter with response ventricular quickly and hemodynamic deterioration, premature ventricular contractions increases during exertion, paroxysmal supraventricular tachycardia uncontrolled.
* Previous infarcts.
* Hypotensive response to exercise.
* Myocardial Ischemia valued at exercise test.
* Unstable Angina.
* Nonrevascularizable disease.
* Poorly controlled hypertension baseline.
* Killip III and IV Killip.
* No collaborator.
* Valvular heart disease associated.
* Pacemaker or Implantable Cardioverter Defibrillator.
* Pathology of musculoskeletal, neurological or breathing that impair the ability of prolonged ambulation.
D: Inclusion Criteria:

* Men and women with documented CVD
* age 40-80 yrs
* patients are on optimal medical treatment and stable with regard to symptoms and pharmacotherapy for at least 4 weeks
* patients must have completed the ambulatory CR program and received clinical approval from their treating physician to continue exercising outside the hospital program
* internet access at home

Exclusion Criteria:

* significant illness during the last 6 weeks
* known severe ventricular arrhythmia with functional or prognostic significance
* significant myocardial ischemia, hemodynamic deterioration or exercise-induced arrhythmia at baseline testing
* cardiac disease that limits exercise tolerance (valve disease with significant hemodynamic consequences, hypertrophic cardiomyopathy etc.)
* co-morbidity that may significantly influence one-year prognosis
* functional or mental disability that may limit exercise
* acute or chronic inflammatory diseases or malignancy, the use of anti-inflammatory drugs or immune suppression
* GFR \<25ml/min/1.73m2
* hemoglobin \< 10g/dl
* severe chronic obstructive pulmonary disease (FEV1 \< 50%)
* NYHA class 4
* participation in another clinical trial

Answer: A